Symbols / MEDP
MEDP Chart
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 12.55B |
| Enterprise Value | 12.19B | Income | 451.12M | Sales | 2.53B |
| Book/sh | 16.18 | Cash/sh | 17.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6200 | IPO | — |
| P/E | 28.96 | Forward P/E | 23.04 | PEG | — |
| P/S | 4.96 | P/B | 27.33 | P/C | — |
| EV/EBITDA | 21.65 | EV/Sales | 4.82 | Quick Ratio | 0.69 |
| Current Ratio | 0.74 | Debt/Eq | 29.81 | LT Debt/Eq | — |
| EPS (ttm) | 15.27 | EPS next Y | 19.19 | EPS Growth | 26.90% |
| Revenue Growth | 32.00% | Earnings | 2026-04-20 | ROA | 16.40% |
| ROE | 70.23% | ROIC | — | Gross Margin | 71.06% |
| Oper. Margin | 21.63% | Profit Margin | 17.83% | Shs Outstand | 28.38M |
| Shs Float | 22.84M | Short Float | 5.97% | Short Ratio | 6.33 |
| Short Interest | — | 52W High | 628.92 | 52W Low | 250.05 |
| Beta | 1.40 | Avg Volume | 314.15K | Volume | 287.92K |
| Target Price | $486.92 | Recom | Hold | Prev Close | $444.96 |
| Price | $442.20 | Change | -0.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$486.92
Mean price target
2. Current target
$442.20
Latest analyst target
3. DCF / Fair value
$299.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$442.20
Low
$329.00
High
$582.00
Mean
$486.92
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | up | TD Cowen | Sell → Hold | $419 |
| 2026-02-13 | up | Jefferies | Hold → Buy | $560 |
| 2026-02-11 | main | Barclays | Underweight → Underweight | $500 |
| 2026-02-11 | main | Truist Securities | Hold → Hold | $539 |
| 2026-02-11 | main | Leerink Partners | Market Perform → Market Perform | $485 |
| 2025-12-15 | main | Barclays | Underweight → Underweight | $525 |
| 2025-11-13 | init | BMO Capital | — → Market Perform | $600 |
| 2025-10-27 | main | Truist Securities | Hold → Hold | $555 |
| 2025-10-24 | main | TD Cowen | Sell → Sell | $462 |
| 2025-10-24 | main | Barclays | Underweight → Underweight | $485 |
| 2025-10-24 | main | Mizuho | Outperform → Outperform | $655 |
| 2025-10-17 | main | Mizuho | Outperform → Outperform | $575 |
| 2025-10-02 | down | Barclays | Equal-Weight → Underweight | $425 |
| 2025-09-09 | main | Jefferies | Hold → Hold | $450 |
| 2025-09-03 | down | Rothschild & Co | Buy → Neutral | $474 |
| 2025-07-29 | down | UBS | Neutral → Sell | $305 |
| 2025-07-25 | main | Mizuho | Outperform → Outperform | $510 |
| 2025-07-23 | main | Truist Securities | Hold → Hold | $436 |
| 2025-07-23 | main | Deutsche Bank | Hold → Hold | $430 |
| 2025-07-23 | main | Barclays | Equal-Weight → Equal-Weight | $450 |
- Medpace (MEDP) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance Fri, 23 Jan 2026 08
- The 'Key Negative' That Took Out Medpace's Sales, Profit Beat - Investor's Business Daily ue, 10 Feb 2026 08
- MEDP: Today's Analyst Rating by TD Cowen | MEDP Stock News - GuruFocus Wed, 18 Feb 2026 19
- $MEDP stock is down 10% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Feb 2026 08
- Assessing Medpace Holdings (MEDP) Valuation After Strong Results, Softer Bookings And New Legal Uncertainty - simplywall.st Mon, 23 Feb 2026 22
- Why Big Stock Swings Like Medpace's 55% Jump Usually Have Clear Causes--Not Market Madness - The Motley Fool Mon, 16 Feb 2026 08
- Medpace Stock (-16%): Guidance Decel Sparks Institutional Selling - Trefis Wed, 11 Feb 2026 11
- Medpace Holdings, Inc. (MEDP) Stock Analysis: Exploring A 14.59% Upside Potential - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- Ongoing Investigation: Medpace Holdings, Inc. (MEDP) May Have Misled Shareholders - Levi & Korsinsky Investigates - marketscreener.com Mon, 23 Feb 2026 05
- Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation (NASDAQ:MEDP) - Seeking Alpha Mon, 09 Feb 2026 08
- Here’s Why Medpace (MEDP) Shares Roared in 2025 - Yahoo Finance Fri, 30 Jan 2026 08
- Medpace Holdings Inc (MEDP) Trading Down 3.61% on Feb 23 - GuruFocus Mon, 23 Feb 2026 17
- New Analyst Forecast: $MEDP Given $485 Price Target - Quiver Quantitative Wed, 11 Feb 2026 12
- Assessing Medpace (MEDP) Valuation After A Sharp Share Price Pullback And Backlog Concerns - Yahoo Finance hu, 12 Feb 2026 08
- MEDP Stock Sees Barclays Lower Price Target to $500 | MEDP Stock News - GuruFocus Wed, 11 Feb 2026 16
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3500 | 486045.0 | — | Conversion of Exercise of derivative security at price 138.87 per share. | EWALD STEPHEN P | General Counsel | — | 2026-02-17 00:00:00 | D |
| 1 | 10984 | 1185503.0 | — | Conversion of Exercise of derivative security at price 107.93 per share. | BURWIG SUSAN ELIZABETH | Officer | — | 2026-02-13 00:00:00 | D |
| 2 | 6472 | 355895.0 | — | Conversion of Exercise of derivative security at price 54.99 per share. | CARLEY BRIAN T | Director | — | 2026-02-13 00:00:00 | D |
| 3 | 56 | nan | — | — | KRAFT ROBERT O | Director | — | 2025-12-31 00:00:00 | D |
| 4 | 62 | nan | — | — | CARLEY BRIAN T | Director | — | 2025-12-31 00:00:00 | D |
| 5 | 49 | nan | — | — | MCCARTHY CORNELIUS P. III | Director | — | 2025-12-31 00:00:00 | D |
| 6 | 10000 | 1079300.0 | — | Conversion of Exercise of derivative security at price 107.93 per share. | BURWIG SUSAN ELIZABETH | Officer | — | 2025-12-05 00:00:00 | D |
| 7 | 668 | 394581.0 | — | Sale at price 590.69 per share. | TROENDLE AUGUST J | Chief Executive Officer | — | 2025-12-03 00:00:00 | D |
| 8 | 28876 | 17114847.0 | — | Sale at price 590.47 - 593.25 per share. | TROENDLE AUGUST J | Chief Executive Officer | — | 2025-12-02 00:00:00 | D |
| 9 | 10000 | 1079300.0 | — | Conversion of Exercise of derivative security at price 107.93 per share. | BURWIG SUSAN ELIZABETH | Officer | — | 2025-12-02 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.30M | -74.40K | -304.78K | 513.25K |
| TaxRateForCalcs | 0.17 | 0.15 | 0.16 | 0.13 |
| NormalizedEBITDA | 570.79M | 476.62M | 365.08M | 297.18M |
| TotalUnusualItems | -7.73M | -496.00K | -1.93M | 3.86M |
| TotalUnusualItemsExcludingGoodwill | -7.73M | -496.00K | -1.93M | 3.86M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 451.12M | 404.39M | 282.81M | 245.37M |
| ReconciledDepreciation | 28.12M | 29.25M | 26.33M | 22.34M |
| ReconciledCostOfRevenue | 1.77B | 1.45B | 1.36B | 1.03B |
| EBITDA | 563.06M | 476.12M | 363.15M | 301.04M |
| EBIT | 534.93M | 446.87M | 336.82M | 278.70M |
| NetInterestIncome | 12.78M | 25.00M | -488.00K | -2.90M |
| NormalizedIncome | 457.56M | 404.81M | 284.43M | 242.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 451.12M | 404.39M | 282.81M | 245.37M |
| TotalExpenses | 2.00B | 1.66B | 1.55B | 1.18B |
| TotalOperatingIncomeAsReported | 534.93M | 446.87M | 336.82M | 278.70M |
| DilutedAverageShares | 32.01M | 31.84M | 33.67M | 37.70M |
| BasicAverageShares | 30.96M | 30.72M | 32.39M | 35.86M |
| DilutedEPS | 12.63 | 8.88 | 7.28 | 4.81 |
| BasicEPS | 13.06 | 9.20 | 7.57 | 5.06 |
| DilutedNIAvailtoComStockholders | 451.12M | 404.34M | 282.62M | 245.21M |
| NetIncomeCommonStockholders | 451.12M | 404.34M | 282.62M | 245.21M |
| OtherunderPreferredStockDividend | 0.00 | 44.00K | 191.00K | 157.00K |
| NetIncome | 451.12M | 404.39M | 282.81M | 245.37M |
| NetIncomeIncludingNoncontrollingInterests | 451.12M | 404.39M | 282.81M | 245.37M |
| NetIncomeContinuousOperations | 451.12M | 404.39M | 282.81M | 245.37M |
| TaxProvision | 91.25M | 71.54M | 52.87M | 37.49M |
| PretaxIncome | 542.38M | 475.92M | 335.68M | 282.86M |
| OtherIncomeExpense | -5.34M | 4.06M | -655.00K | 7.07M |
| OtherNonOperatingIncomeExpenses | 2.39M | 4.55M | 1.27M | 3.21M |
| GainOnSaleOfSecurity | -7.73M | -496.00K | -1.93M | 3.86M |
| NetNonOperatingInterestIncomeExpense | 12.78M | 25.00M | -488.00K | -2.90M |
| TotalOtherFinanceCost | -12.78M | -25.00M | 488.00K | 2.90M |
| OperatingIncome | 534.93M | 446.87M | 336.82M | 278.70M |
| OperatingExpense | 225.68M | 209.44M | 187.68M | 153.74M |
| DepreciationAmortizationDepletionIncomeStatement | 28.12M | 29.25M | 26.33M | 22.34M |
| DepreciationAndAmortizationInIncomeStatement | 28.12M | 29.25M | 26.33M | 22.34M |
| Amortization | 946.00K | 1.44M | 2.20M | 3.35M |
| AmortizationOfIntangiblesIncomeStatement | 946.00K | 1.44M | 2.20M | 3.35M |
| DepreciationIncomeStatement | 27.18M | 27.81M | 24.13M | 18.99M |
| SellingGeneralAndAdministration | 197.56M | 180.18M | 161.35M | 131.40M |
| GrossProfit | 760.62M | 656.30M | 524.50M | 432.44M |
| CostOfRevenue | 1.77B | 1.45B | 1.36B | 1.03B |
| TotalRevenue | 2.53B | 2.11B | 1.89B | 1.46B |
| OperatingRevenue | 2.53B | 2.11B | 1.89B | 1.46B |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 69.62K | 70.07K | 70.57K | 71.57K |
| OrdinarySharesNumber | 28.37M | 30.63M | 30.75M | 31.09M |
| ShareIssued | 28.44M | 30.70M | 30.82M | 31.16M |
| NetDebt | 21.73M | |||
| TotalDebt | 113.64M | 126.23M | 142.12M | 188.87M |
| TangibleBookValue | -236.75M | 128.78M | -139.25M | -314.02M |
| InvestedCapital | 459.07M | 825.54M | 558.95M | 436.39M |
| WorkingCapital | -354.12M | -75.32M | -331.30M | -469.51M |
| NetTangibleAssets | -236.75M | 128.78M | -139.25M | -314.02M |
| CapitalLeaseObligations | 113.64M | 126.23M | 142.12M | 138.87M |
| CommonStockEquity | 459.07M | 825.54M | 558.95M | 386.39M |
| TotalCapitalization | 459.07M | 825.54M | 558.95M | 386.39M |
| TotalEquityGrossMinorityInterest | 459.07M | 825.54M | 558.95M | 386.39M |
| StockholdersEquity | 459.07M | 825.54M | 558.95M | 386.39M |
| GainsLossesNotAffectingRetainedEarnings | -4.91M | -14.74M | -10.07M | -12.39M |
| OtherEquityAdjustments | -4.91M | -14.74M | -10.07M | -12.39M |
| TreasuryStock | 12.16M | 12.23M | 12.32M | 12.50M |
| RetainedEarnings | -459.98M | 8.17M | -221.65M | -359.83M |
| AdditionalPaidInCapital | 935.83M | 844.05M | 802.68M | 770.79M |
| CapitalStock | 284.00K | 306.00K | 308.00K | 309.00K |
| CommonStock | 284.00K | 306.00K | 308.00K | 309.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.52B | 1.28B | 1.10B | 966.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 172.65M | 170.77M | 172.75M | 162.64M |
| OtherNonCurrentLiabilities | 57.66M | 42.73M | 28.22M | 22.70M |
| NonCurrentDeferredLiabilities | 1.35M | 1.80M | 2.40M | 1.07M |
| NonCurrentDeferredTaxesLiabilities | 1.35M | 1.80M | 2.40M | 1.07M |
| LongTermDebtAndCapitalLeaseObligation | 113.64M | 126.23M | 142.12M | 138.87M |
| LongTermCapitalLeaseObligation | 113.64M | 126.23M | 142.12M | 138.87M |
| CurrentLiabilities | 1.34B | 1.10B | 925.13M | 803.47M |
| OtherCurrentLiabilities | 52.83M | 53.63M | 40.44M | 47.55M |
| CurrentDeferredLiabilities | 854.39M | 710.59M | 559.86M | 462.73M |
| CurrentDeferredRevenue | 854.39M | 710.59M | 559.86M | 462.73M |
| CurrentDebtAndCapitalLeaseObligation | 50.00M | |||
| CurrentDebt | 50.00M | |||
| LineOfCredit | 0.00 | 50.00M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 80.14M | 84.93M | 75.82M | 71.20M |
| PayablesAndAccruedExpenses | 356.38M | 255.41M | 249.01M | 172.00M |
| CurrentAccruedExpenses | 328.24M | 222.88M | 217.14M | 138.93M |
| Payables | 28.14M | 32.53M | 31.87M | 33.07M |
| AccountsPayable | 28.14M | 32.53M | 31.87M | 33.07M |
| TotalAssets | 1.98B | 2.10B | 1.66B | 1.35B |
| TotalNonCurrentAssets | 985.85M | 1.07B | 1.06B | 1.02B |
| OtherNonCurrentAssets | 21.94M | 22.25M | 24.97M | 21.13M |
| NonCurrentDeferredAssets | 19.22M | 100.36M | 74.44M | 48.08M |
| NonCurrentDeferredTaxesAssets | 19.22M | 100.36M | 74.44M | 48.08M |
| GoodwillAndOtherIntangibleAssets | 695.82M | 696.76M | 698.21M | 700.40M |
| OtherIntangibleAssets | 33.42M | 34.37M | 35.81M | 38.01M |
| Goodwill | 662.40M | 662.40M | 662.40M | 662.40M |
| NetPPE | 248.87M | 252.26M | 265.39M | 248.92M |
| AccumulatedDepreciation | -123.27M | -98.87M | -79.40M | -62.12M |
| GrossPPE | 372.14M | 351.13M | 344.79M | 311.03M |
| ConstructionInProgress | 12.77M | 21.17M | 7.18M | 10.52M |
| OtherProperties | 171.17M | 174.29M | 184.73M | 170.92M |
| MachineryFurnitureEquipment | 142.61M | 134.83M | 131.63M | 113.59M |
| BuildingsAndImprovements | 40.45M | 15.81M | 16.42M | 13.59M |
| LandAndImprovements | 5.14M | 5.03M | 4.83M | 2.41M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 989.62M | 1.03B | 593.83M | 333.96M |
| OtherCurrentAssets | 90.50M | 63.35M | 49.98M | 52.29M |
| PrepaidAssets | 43.18M | |||
| Receivables | 402.08M | 296.44M | 298.40M | 253.40M |
| ReceivablesAdjustmentsAllowances | -29.00K | 0.00 | -7.00K | -170.00K |
| OtherReceivables | 25.35M | 5.35M | 22.48M | 40.41M |
| AccountsReceivable | 376.75M | 291.10M | 275.93M | 213.17M |
| CashCashEquivalentsAndShortTermInvestments | 497.05M | 669.44M | 245.45M | 28.27M |
| CashAndCashEquivalents | 497.05M | 669.44M | 245.45M | 28.27M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 681.87M | 572.27M | 396.73M | 351.17M |
| RepurchaseOfCapitalStock | -917.39M | -169.87M | -144.02M | -847.85M |
| RepaymentOfDebt | 0.00 | 0.00 | -155.00M | -274.20M |
| IssuanceOfDebt | 0.00 | 0.00 | 105.00M | 324.20M |
| CapitalExpenditure | -31.36M | -36.55M | -36.65M | -36.88M |
| InterestPaidSupplementalData | 0.00 | 171.00K | 3.06M | 2.94M |
| IncomeTaxPaidSupplementalData | 39.72M | 83.57M | 76.35M | 50.16M |
| EndCashPosition | 497.05M | 669.44M | 245.45M | 28.27M |
| BeginningCashPosition | 669.44M | 245.45M | 28.27M | 461.30M |
| EffectOfExchangeRateChanges | 5.92M | -2.51M | 1.08M | -6.57M |
| ChangesInCash | -178.31M | 426.50M | 216.10M | -426.47M |
| FinancingCashFlow | -860.39M | -154.01M | -182.64M | -775.77M |
| CashFlowFromContinuingFinancingActivities | -860.39M | -154.01M | -182.64M | -775.77M |
| ProceedsFromStockOptionExercised | 57.00M | 15.86M | 11.38M | 22.07M |
| NetCommonStockIssuance | -917.39M | -169.87M | -144.02M | -847.85M |
| CommonStockPayments | -917.39M | -169.87M | -144.02M | -847.85M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -50.00M | 50.00M |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -50.00M | 50.00M |
| ShortTermDebtPayments | 0.00 | 0.00 | -155.00M | -274.20M |
| ShortTermDebtIssuance | 0.00 | 0.00 | 105.00M | 324.20M |
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| InvestingCashFlow | -31.14M | -28.31M | -34.63M | -38.74M |
| CashFlowFromContinuingInvestingActivities | -31.14M | -28.31M | -34.63M | -38.74M |
| NetOtherInvestingChanges | 216.00K | 8.24M | 2.02M | -1.86M |
| NetPPEPurchaseAndSale | -31.36M | -36.55M | -36.65M | -36.88M |
| PurchaseOfPPE | -31.36M | -36.55M | -36.65M | -36.88M |
| CapitalExpenditureReported | -28.27M | |||
| OperatingCashFlow | 713.22M | 608.82M | 433.37M | 388.05M |
| CashFlowFromContinuingOperatingActivities | 713.22M | 608.82M | 433.37M | 388.05M |
| ChangeInWorkingCapital | 96.28M | 157.18M | 106.49M | 106.06M |
| ChangeInOtherWorkingCapital | 155.04M | 174.52M | 87.52M | 140.14M |
| ChangeInOtherCurrentLiabilities | -25.16M | -21.41M | -18.87M | -15.90M |
| ChangeInPayablesAndAccruedExpense | 99.71M | 13.92M | 83.13M | 58.91M |
| ChangeInAccruedExpense | 97.08M | 16.88M | 82.08M | 52.48M |
| ChangeInPayable | 2.63M | -2.96M | 1.05M | 6.43M |
| ChangeInAccountPayable | 2.63M | -2.96M | 1.05M | 6.43M |
| ChangeInPrepaidAssets | -27.10M | -12.09M | 2.99M | -10.18M |
| ChangeInReceivables | -106.22M | 2.24M | -48.28M | -66.92M |
| OtherNonCashItems | 22.14M | 19.11M | 22.35M | 15.89M |
| StockBasedCompensation | 34.79M | 25.51M | 20.52M | 21.41M |
| DeferredTax | 80.77M | -26.63M | -25.12M | -23.01M |
| DeferredIncomeTax | 80.77M | -26.63M | -25.12M | -23.01M |
| DepreciationAmortizationDepletion | 28.12M | 29.25M | 26.33M | 22.34M |
| DepreciationAndAmortization | 28.12M | 29.25M | 26.33M | 22.34M |
| AmortizationCashFlow | 946.00K | 1.44M | 2.20M | 3.35M |
| AmortizationOfIntangibles | 946.00K | 1.44M | 2.20M | 3.35M |
| Depreciation | 27.18M | 27.81M | 24.13M | 18.99M |
| NetIncomeFromContinuingOperations | 451.12M | 404.39M | 282.81M | 245.37M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MEDP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|